Skip to main content

CORRECTION article

Front. Cell Dev. Biol., 16 March 2023
Sec. Molecular and Cellular Pathology
Volume 11 - 2023 | https://doi.org/10.3389/fcell.2023.1179559

Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer

This article is a correction to:

  1. Clinical Impact of Molecular Subtyping of Pancreatic Cancer

    1. Read original article
Xu Zhou,Xu Zhou1,2Kai Hu,Kai Hu1,2Peter Bailey,,Peter Bailey1,2,3Christoph SpringfeldChristoph Springfeld4Susanne RothSusanne Roth1Roma KurilovRoma Kurilov5Benedikt Brors,Benedikt Brors4,5Thomas GressThomas Gress6Malte BuchholzMalte Buchholz6Jingyu An,Jingyu An1,2Kongyuan Wei,Kongyuan Wei1,2Teresa Peccerella,Teresa Peccerella1,2Markus W. BüchlerMarkus W. Büchler1Thilo HackertThilo Hackert1John P. Neoptolemos, John P. Neoptolemos1,2*
  • 1Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany
  • 2Section of Surgical Research, Heidelberg University Hospital, Heidelberg, Germany
  • 3Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
  • 4Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
  • 5Division of Applied Bioinformatics, German Cancer Research Center, Heidelberg, Germany
  • 6Department of Gastroenterology and Endocrinology, Philipps University of Marburg, Marburg, Germany

A Corrigendum on
Clinical impact of molecular subtyping of pancreatic cancer

by Zhou X, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T and Neoptolemos JP (2021). Front. Cell Dev. Biol. 9:743908. doi: 10.3389/fcell.2021.743908

In the published article, an author name was incorrectly written as Zhou Xu. The correct spelling is “Xu Zhou”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: molecular subtypes, transcriptomes, structural variants, precision medicine, next generation sequencing, clinical trials, ESPAC

Citation: Zhou X, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T and Neoptolemos JP (2023) Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. Front. Cell Dev. Biol. 11:1179559. doi: 10.3389/fcell.2023.1179559

Received: 04 March 2023; Accepted: 06 March 2023;
Published: 16 March 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Zhou, Hu, Bailey, Springfeld, Roth, Kurilov, Brors, Gress, Buchholz, An, Wei, Peccerella, Büchler, Hackert and Neoptolemos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: John P. Neoptolemos, john.neoptolemos@med.uni-heidelberg.de

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.